Protalix BioTherapeutics, Inc. (DE) (PLX): Price and Financial Metrics
PLX Price/Volume Stats
| Current price | $1.18 | 52-week high | $3.55 |
| Prev. close | $1.16 | 52-week low | $1.09 |
| Day low | $1.18 | Volume | 1,107 |
| Day high | $1.18 | Avg. volume | 334,477 |
| 50-day MA | $1.31 | Dividend yield | N/A |
| 200-day MA | $1.55 | Market Cap | 86.51M |
PLX Stock Price Chart Interactive Chart >
Protalix BioTherapeutics, Inc. (DE) (PLX) Company Bio
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company was founded in 1993 and is based in Carmiel, Israel.
Latest PLX News From Around the Web
Below are the latest news stories about PROTALIX BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate PLX as an investment opportunity.
Protalix BioTherapeutics Issues 2024 Letter to StockholdersProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders. |
Levicept Appoints Eliot Forster as CEOLeadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty y |
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript November 6, 2023 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Good morning, ladies and gentlemen. And welcome to the Protalix Biotherapeutics Third Quarter 2023 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I […] |
PLX: More Regulatory ApprovalsBy John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2023 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 3Q:23 financial and operational results in a November 6th, 2023 press release and filing of Form 10-Q . The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial |
Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial ResultsProtalix BioTherapeutics Inc (PLX) reported a net income of $14.36 million for Q3 2023, a significant improvement from a loss of $11.19 million in the same period last year. The company's cash and cash equivalents increased to $20.41 million from $17.11 million at the end of 2022. Protalix continues to advance its clinical trial of PRX-115, a potential treatment for severe gout, with top-line results expected in mid-2024. |
PLX Price Returns
| 1-mo | -4.84% |
| 3-mo | -18.62% |
| 6-mo | -36.22% |
| 1-year | -64.88% |
| 3-year | -60.00% |
| 5-year | -72.95% |
| YTD | -33.71% |
| 2023 | 29.93% |
| 2022 | 64.72% |
| 2021 | -77.09% |
| 2020 | 10.67% |
| 2019 | 5.47% |
Continue Researching PLX
Want to see what other sources are saying about Protalix BioTherapeutics Inc's financials and stock price? Try the links below:Protalix BioTherapeutics Inc (PLX) Stock Price | Nasdaq
Protalix BioTherapeutics Inc (PLX) Stock Quote, History and News - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...